Concepedia

Author

Tomoki Yoneyama

Takeda (Japan)ORCID

Also Known As

T YONEYAMA, T Yoneyama, T. Yoneyama, Tomoki Yoneyama

85

Publications

774

Citations

10

H-Index

36

Concepts

All Affiliations

Takeda (Japan)Takeda (United States)Takeda (United Kingdom)Oida HospitalSaiseikai Nakatsu Hospital
TY

About

Tomoki Yoneyama is an author at Takeda (Japan) specializing in medicine, immunology, and tumor microenvironment.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

107

2

Biochemistry

2

2

52

3

Engineering

1

1

24

4

Natural Sciences

1

1

14

5

Biomolecular Engineering

1

1

14

Tomoki Yoneyama

×

9

Publications

634

Citations

9

H-Index

YearCitations

Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of <scp>TAK</scp>‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjects

Helen Jenkins, Yuichi Sakurai, Akira Nishimura,

Alimentary Pharmacology & Therapeutics

2015

294

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects

Yuuichi Sakurai, Akira Nishimura, Gale Kennedy,

Clinical and Translational Gastroenterology

2015

188

A validated simultaneous quantification method for vonoprazan (TAK-438F) and its 4 metabolites in human plasma by the liquid chromatography-tandem mass spectrometry

Tomoki Yoneyama, Koichiro Teshima, Fumihiro Jinno,

Journal of Chromatography B

2016

38

Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti‐allodynic effects

Masashi Ueda, Yuki Iida, Akiko Tominaga,

British Journal of Pharmacology

2010

24

Tiered Approaches to Chromatographic Bioanalytical Method Performance Evaluation: Recommendation for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team

Steve Lowes, Richard Hucker, Mohammed Jemal,

The AAPS Journal

2014

24

Advanced translational PBPK model for transferrin receptor-mediated drug delivery to the brain

Sho Sato, Siyu Liu, Akihiko Goto,

Journal of Controlled Release

2023

21

Phase 1a/1b study design of the novel STING agonist, immune-stimulating antibody-conjugate (ISAC) TAK-500, with or without pembrolizumab in patients with advanced solid tumors.

Jennifer R. Diamond, Jason T. Henry, Gerald S. Falchook,

Journal of Clinical Oncology

2022

18

Chemical reactivity of ethyl (6R)-6-[N-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242) in vitro

Fumihiro Jinno, Tomoki Yoneyama, Akio Morohashi,

Biopharmaceutics & Drug Disposition

2011

14

Leveraging a physiologically-based quantitative translational modeling platform for designing B cell maturation antigen-targeting bispecific T cell engagers for treatment of multiple myeloma

Tomoki Yoneyama, Mi‐Sook Kim, Konstantin Piatkov,

PLoS Computational Biology

2022

13

Page 1